BPC-157 vs Thymulin Analog (PAT)
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
Synthetic thymulin-derived nonapeptide with potent analgesic and anti-inflammatory properties
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
BPC-157
250–500 mcg
Thymulin Analog (PAT)
1 mcg–50 mcg mcg
Frequency
BPC-157
Once daily
Thymulin Analog (PAT)
Once daily
Administration
BPC-157
Subcutaneous injection
Thymulin Analog (PAT)
Intraperitoneal injection
Cycle length
BPC-157
4-6 weeks
Thymulin Analog (PAT)
Ongoing/indefinite
Onset speed
BPC-157
Moderate (1-2 weeks)
Thymulin Analog (PAT)
Moderate (1-2 weeks)
Evidence level
BPC-157
Strong preclinical (extensive animal studies)
Thymulin Analog (PAT)
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Primary Benefit
Secondary Benefit
Additional Benefit
Pain Relief
Anti-Inflammatory
Neuroprotection
Compound specifications
BPC-157
Molecular formula
C62H98N16O22
Molecular weight
1419.53 g/mol
Half-life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS number
137525-51-0
Thymulin Analog (PAT)
Molecular formula
C37H62N12O15
Molecular weight
858.9 Da
Half-life
Effects peak at 1-2 hours; diminish by 3-4 hours post-single dose
Bioavailability
Effective via intraperitoneal and intracerebroventricular routes in preclinical models
CAS number
Not assigned
Dosing compared
BPC-157
Subcutaneous
250 mcg
Once daily · 1-2 weeks
A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
250-500 mcg
Twice daily · 4-6 weeks
Commonly used range for tissue and tendon recovery in research practice [1][3].
500 mcg
Twice daily · 6-8 weeks
Upper end used in practice for more demanding acute injuries [1][3].
Thymulin Analog (PAT)
Best suited for
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair [1][7]
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions [1][11] - derived from gastric juice, it has a natural affinity for digestive tissue [3][5]
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression [8]
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties [9][10]
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms [2]
Thymulin Analog (PAT)
Neuropathic pain research
Thymulin Analog (PAT) is particularly well-suited for individuals focused on neuropathic pain research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-inflammatory therapy development
Thymulin Analog (PAT) is particularly well-suited for individuals focused on anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Novel analgesic mechanism investigation
Thymulin Analog (PAT) is particularly well-suited for individuals focused on novel analgesic mechanism investigation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cytokine-mediated pain pathway studies
Thymulin Analog (PAT) is particularly well-suited for individuals focused on cytokine-mediated pain pathway studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Thymulin Analog (PAT)
Common
- Injection Site Reaction
- Transient Immune Modulation
- Mild Sedation
- Short Duration of Action
Uncommon
- Potential Immune Suppression
- CNS Effects with Central Administration
Serious
- Unintended Immune Stimulation
Safety & evidence
BPC-157
Evidence level
Strong preclinical (extensive animal studies)
FDA status
Research compound
Safety overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. [5] No FDA approval exists. [4][6] Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. [4][5] Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. [2][4] The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. [6][7] Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- Pregnancy
- Breastfeeding
- Active cancer
- History of cancer
Thymulin Analog (PAT)
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Research compound
Safety overview
Thymulin Analog (PAT) is a synthetic 9-amino acid peptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that is a research compound ONLY—NOT approved for human use. No serious adverse effects have been documented in extensive preclinical studies spanning 17+ years. However, this is a critical limitation: all data comes from animal models (primarily rats and mice). Zero completed human clinical trials exist. The peptide has not undergone human Phase 1 safety testing. No manufactured batches meet pharmaceutical standards. PAT's primary mechanism—alpha-7 nAChR potentiation—could theoretically affect multiple organ systems, but human safety data is absent. As an immune-modulating compound, prolonged high-dose use could theoretically suppress protective immunity, though animal studies show no adverse effects at therapeutic doses. Individual responses in humans are completely unknown.
Contraindications
- Not approved for human use
- Potential immune modulation concerns with chronic use
- Unknown drug-drug interactions
- Pregnancy and lactation (insufficient safety data)
Which is right for you?
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health
Choose Thymulin Analog (PAT) if...
- Neuropathic pain research
- Anti-inflammatory therapy development
- Novel analgesic mechanism investigation
- Cytokine-mediated pain pathway studies